Pfizer, BioNTech Report Positive Data From Omicron-adapted COVID-19 Vaccine Candidate Trial
Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced positive data from the Phase 2/3 trial evaluating the safety, tolerability, and immunogenicity of Omicron-adapted COVID-19 vaccine candidates against Omicron. The companies reported positive data from two trials-one as a monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting […]
Continue Reading